New anticoagulants - Promising and failed developments

British Journal of Pharmacology

Volumn 165, Issue 2, 2012, Pages 363-372

  Harenberg, Job ^a   Marx, Svetlana ^a   Krejczy, Martin ^a   Wehling, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

anticoagulants; atrial fibrillation; factor Xa inhibitors; thrombin inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTICOAGULANT AGENT; APIXABAN; ARGATROBAN; AZD 0837; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; DAREXABAN; DIGOXIN; EDOXABAN; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; IDRABIOTAPARINUX; IDRAPARINUX; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; NAPROXEN; OTAMIXABAN; PLACEBO; RIVAROXABAN; SEMULOPARIN; SR 123781; TAK 421; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BLEEDING; BRAIN EMBOLISM; BRAIN HEMORRHAGE; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPEPSIA; EMBOLISM; FOOD; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; STROKE; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; FACTOR XA; HUMANS; THROMBIN; THROMBOEMBOLISM;

EID: 83755224350     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01578.x     Document Type: Review

References (48)

1. Aalbers J, (2011). Special Assignment Editor Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke. Cardiovasc J Afr 21: 342-343.
2. Agnelli G, Haas S, Ginsberg JS, Krueger KA, Dmitrienko A, Brandt JT, (2007). A phase II study of the safety and efficacy of a novel oral fXa inhibitor (LY517717) for the prevention of venous thromboembolism following TKR or THR. J Thromb Haemost 5: 746-753. (Pubitemid 46563573)
3. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, et al,. (2009). Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119: 2877-2885.
4. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, (2008). Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 133: 160S-198S. (Pubitemid 351892967)
5. Baker WL, Cios DA, Sander SD, Coleman CI, (2009). Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 15: 244-252.
6. Becker RC, Thomas W, Meade PB, Berger M, Ezekowitz CM, O'Connor DA, et al,. (2008). The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 133: 776S-814S. (Pubitemid 351894917)
7. Cao YB, Zhang JD, Shen H, Jiang YY, (2010). Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 66: 1099-1108.
8. Cohen M, Bhatt DL, Alexander JH, Montalescot G, Bode C, Henry T, et al,. on behalf of the SEPIA-PCI Trial Investigators (2007). Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 115: 2642-2651. (Pubitemid 46791363)
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al,. (2009). RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
10. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al,. (2011). The AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 364: 806-817.
11. Deinum J, Mattsson C, Inghardt T, Elg M, (2009). Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost 101: 1051-1059.
12. Direct Thrombin Inhibitor Trialists' Collaborative Group (2002). Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients. Lancet 359: 294-302.
13. Eikelboom JW, Zelenkofske SL, Rusconi CP, (2010). Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arterioscler Thromb Vasc Biol 30: 382-387.
14. Equinox Investigators (2011). Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 9: 92-99.
15. Eriksson BI, Turpie AG, Lassen MR, et al,. for the ONYX STUDY GROUP (2007). A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 5: 1660-1665. (Pubitemid 47091408)
16. Eriksson BI, Quinlan DJ, Weitz JI, (2009). Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 48: 1-22.
17. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, et al,. (2011). Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 154: 1-11.
18. Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, et al,. (2010). RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 126: 175-182.
19. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ, (2001). Validation of clinical classification schemes for predicting stroke. JAMA 285: 2864-2870.
20. Gustafsson D, Elg M, (2003). The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran. Thromb Res 109: S9-S15. (Pubitemid 36724832)
21. Harenberg J, (2008). Development of new anticoagulants: present and future. Semin Thromb Hemost 34: 779-793.
22. Harenberg J, (2009). Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 102: 811-815.
23. Harenberg J, Jörg I, Vukojevic Y, Mikus G, Weiss C, (2008a). Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur J Clin Pharmacol 64: 555-563.
24. Harenberg J, Vukojevic Y, Mikus G, Joerg I, Weiss C, (2008b). Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. J Thromb Haemost 6: 890-892. (Pubitemid 351524554)
25. Hauptmann J, Stürzebecher J, (1999). Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb Res 93: 203-241. (Pubitemid 29130456)
26. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI, (2008). Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 133: 141S-159S. (Pubitemid 351892966)
27. Kawamura M, Konishi N, Hiroe K, Shofuda K, Imaeda Y, Fujimoto T, et al,. (2010). Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis. J Cardiovasc Pharmacol 56: 156-161.
28. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al,. (1999). A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340: 901-917.
29. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, (2008). Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 133: 454S-545S. (Pubitemid 351892971)
30. de Kort M, Buijsman RC, van Boeckel CA, (2005). Synthetic heparin derivatives as new anticoagulant drugs. Drug Discov Today 10: 769-779. (Pubitemid 40744921)
31. Kubitza D, Haas S, (2006). Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 15: 843-855. (Pubitemid 44177839)
32. Lassen MR, Dahl O, Mismetti P, Zielske D, Turpie AG, (2008). SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study. J Am Coll Cardiol 51: 1498-1504. (Pubitemid 351470038)
33. Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG, (2009). AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery-TREK: a dose-ranging study. J Thromb Haemost 7: 566-572.
34. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ, (2010). Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137: 263-272.
35. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al,. (2009). Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374: 29-38.
36. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al,. (2011). Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. [Epub ahead of print].
37. Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, et al,. (2007). Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl) -4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 50: 5339-5356. (Pubitemid 350057846)
38. ROCKET AF Study Investigators (2010). Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 159: 340-347.
39. Schulman S, Wà¥hlander K, Lundström T, Clason SB, Eriksson H, THRIVE III Investigators (2003). Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 349: 1713-1721. (Pubitemid 37315008)
40. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al,. (2009). RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361: 2342-2352.
41. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al,. (2008). Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 133: 546S-592S. (Pubitemid 351892972)
42. The EINSTEIN Investigators (2010). Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363: 2499-2510.
43. Tulner LR, Van Campen JP, Kuper IM, Gijsen GJ, Koks CH, Mac Gillavry MR, et al,. (2010). Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging 27: 39-50.
44. Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, et al,. (2009). EXPERT Study Group. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 101: 68-76.
45. Warkentin TE, Greinacher A, Koster A, Lincoff AM, (2008). Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 133: 340S-380S. (Pubitemid 351892970)
46. Weitz JI, Cao C, Eriksson BI, Fisher W, Kupfer S, Raskob G, et al,. (2010). A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost 104: 1150-1157.
47. Wong PC, Pinto DJ, Zhang D, (2011). Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 31: 478-492.
48. Zafar MU, Vorchheimer DA, Gaztanaga J, Velez M, Yadegar D, Moreno PR, et al,. (2007). Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 98: 883-888. (Pubitemid 47555083)